Denmark among EU elite in biotech  

A new report by Cap Gemini/Ernst & Young shows that Denmark is one of the most attractive places in the EU for establishing biotech companies

A new report by Cap Gemini/Ernst & Young, EU Enlargement – Driving Change in the European Life Science Industry, shows that Denmark is one of the best countries in the EU for establishing biotech companies. The country leads the way in healthcare research, and together with Finland and Luxembourg it has the best legislative structures for creating an efficient business climate and competition in the healthcare industry. Denmark and Finland are also the countries with least bureaucracy in the EU and both are considered to be the most attractive for lifescience research investments.


The analysis concludes however that Denmark does not receive as much biotech investment as its quality entitles it to. Hanne Buus van der Kam, senior consultant at Cap Gemini/Ernst & Young says Denmark is not good enough at drawing attention to itself; the benefits offered to biotech companies in Medicon Valley should be a magnet to them. The news is reported by Biotech Denmark online.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×